We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
Trial record 17 of 204 for:    Oral Cancer | Recruiting Studies | NIH

Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02723864
Recruitment Status : Recruiting
First Posted : March 31, 2016
Last Update Posted : February 14, 2018
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) )

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : December 31, 2018
  Estimated Study Completion Date : December 31, 2018